Details for New Drug Application (NDA): 217217
✉ Email this page to a colleague
NDA 217217 describes DASATINIB, which is a drug marketed by Apotex, Biocon Pharma, Dr Reddys, and Zydus Pharms, and is included in five NDAs. It is available from five suppliers. Additional details are available on the DASATINIB profile page.
The generic ingredient in DASATINIB is dasatinib. There are fourteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the dasatinib profile page.
The generic ingredient in DASATINIB is dasatinib. There are fourteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the dasatinib profile page.
Summary for 217217
| Tradename: | DASATINIB |
| Applicant: | Biocon Pharma |
| Ingredient: | dasatinib |
| Patents: | 0 |
Pharmacology for NDA: 217217
| Mechanism of Action | Cytochrome P450 3A4 Inhibitors Protein Kinase Inhibitors |
Medical Subject Heading (MeSH) Categories for 217217
Suppliers and Packaging for NDA: 217217
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DASATINIB | dasatinib | TABLET;ORAL | 217217 | ANDA | Biocon Pharma Inc. | 70377-083 | 70377-083-11 | 60 TABLET, FILM COATED in 1 BOTTLE (70377-083-11) |
| DASATINIB | dasatinib | TABLET;ORAL | 217217 | ANDA | Biocon Pharma Inc. | 70377-084 | 70377-084-11 | 60 TABLET, FILM COATED in 1 BOTTLE (70377-084-11) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 20MG | ||||
| Approval Date: | Mar 3, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
| Approval Date: | Mar 3, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 70MG | ||||
| Approval Date: | Mar 3, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
